Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > More Validation

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Jun 06, 2024 8:34pm

144 Views

Post# 36076664

RE:More Validation

Welcome back CancerSlayer! I don't know the answer to that one - it might be out there in the interweb but it would take some searching.

CancerSlayer wrote: Thanks Eoganacht....

Just catching up on some news after an extended holiday...delighted to see the continued scientific validation of this tech. The potential clinical versatility of this drug (against multiple cancer types & infectious diseses) is truly remarkable.

As for the FDA, I'm curious as to why a central path lab wasn't recommended at a much earlier stage in the trial (i.e. post fast track designation)? Do you know if other NMIBC trials have been held to the same "central path lab" standard, or is this a new bar being set for this indication? Makes sense that the above requirement should have been clearly communicated & in place for all NMIBC studies at the beginning of Ph 2....JMO. Good luck...